Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology company specializing in Fibroblast Growth Factor Receptor (FGFR) biology, has announced its participation in four major upcoming investor conferences in early 2025.
The company will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (February 11-12, virtual), the TD Cowen 45th Annual Healthcare Conference (March 3-5, Boston), the Jefferies Biotech on the Beach Summit (March 11-12, Miami), and the Barclays 27th Annual Global Healthcare Conference (March 11-13, Miami).
Management will engage in fireside chats and one-on-one investor meetings at most events, with presentations scheduled for February 12 at 2:00 PM ET (Oppenheimer), March 3 at 9:50 AM ET (TD Cowen), and March 12 at 8:30 AM ET (Barclays). Live and archived webcasts of the fireside chats will be accessible through TYRA's investor relations website.
Tyra Biosciences (NASDAQ: TYRA), una compagnia biotecnologica in fase clinica specializzata nella biologia del recettore del fattore di crescita dei fibroblasti (FGFR), ha annunciato la sua partecipazione a quattro importanti conferenze per investitori in programma all'inizio del 2025.
La società prenderà parte alla 35a Conferenza Annuale sulla Salute e le Scienze della Vita Oppenheimer (11-12 febbraio, virtuale), alla 45a Conferenza Annuale sulla Salute TD Cowen (3-5 marzo, Boston), al Summit Jefferies Biotech on the Beach (11-12 marzo, Miami) e alla 27a Conferenza Globale Annuale sulla Salute Barclays (11-13 marzo, Miami).
Il management parteciperà a conversazioni informali e incontri individuali con investitori in gran parte degli eventi, con presentazioni programmate per il 12 febbraio alle 14:00 ET (Oppenheimer), il 3 marzo alle 9:50 ET (TD Cowen), e il 12 marzo alle 8:30 ET (Barclays). Le dirette e le registrazioni dei webcast delle conversazioni informali saranno accessibili tramite il sito web delle relazioni con gli investitori di TYRA.
Tyra Biosciences (NASDAQ: TYRA), una empresa biotecnológica en etapa clínica especializada en biología del receptor del factor de crecimiento de fibroblastos (FGFR), ha anunciado su participación en cuatro importantes conferencias para inversores programadas para principios de 2025.
La empresa participará en la 35ª Conferencia Anual de Ciencias de la Vida y Salud de Oppenheimer (11-12 de febrero, virtual), en la 45ª Conferencia Anual de Salud de TD Cowen (3-5 de marzo, Boston), en el Summit Jefferies Biotech en la Playa (11-12 de marzo, Miami) y en la 27ª Conferencia Global Anual de Salud de Barclays (11-13 de marzo, Miami).
La gerencia participará en charlas informales y reuniones uno a uno con inversores en la mayoría de los eventos, con presentaciones programadas para el 12 de febrero a las 2:00 PM ET (Oppenheimer), el 3 de marzo a las 9:50 AM ET (TD Cowen), y el 12 de marzo a las 8:30 AM ET (Barclays). Las transmisiones en vivo y grabadas de las charlas informales estarán disponibles a través del sitio web de relaciones con inversores de TYRA.
Tyra Biosciences (NASDAQ: TYRA)는 섬유아세포 성장 인자 수용체(FGFR) 생물학을 전문으로 하는 임상 단계 생명공학 회사로, 2025년 초에 예정된 4개의 주요 투자자 회의에 참가한다고 발표했습니다.
회사는 Oppenheimer 제35회 연례 건강 및 생명과학 컨퍼런스 (2월 11-12일, 가상), TD Cowen 제45회 연례 건강 회의 (3월 3-5일, 보스턴), Jefferies Biotech on the Beach Summit (3월 11-12일, 마이애미), Barclays 제27회 글로벌 건강 회의 (3월 11-13일, 마이애미)에 참가할 예정입니다.
경영진은 대부분의 행사에서 파이어사이드 챗과 일대일 투자자 회의에 참여할 예정이며, 발표는 Oppenheimer에서 2월 12일 오후 2시(ET), TD Cowen에서 3월 3일 오전 9시 50분(ET), Barclays에서 3월 12일 오전 8시 30분(ET)으로 예정되어 있습니다. 파이어사이드 챗의 실시간 및 아카이브 웹캐스트는 TYRA의 투자자 관계 웹사이트를 통해 접근할 수 있습니다.
Tyra Biosciences (NASDAQ: TYRA), une entreprise de biotechnologie en phase clinique spécialisée dans la biologie du récepteur du facteur de croissance des fibroblastes (FGFR), a annoncé sa participation à quatre grandes conférences d'investisseurs prévues début 2025.
L'entreprise participera à la 35ème Conférence Annuelle de la Santé et des Sciences de la Vie Oppenheimer (11-12 février, virtuel), à la 45ème Conférence Annuelle de la Santé TD Cowen (3-5 mars, Boston), au Sommet Jefferies Biotech on the Beach (11-12 mars, Miami) et à la 27ème Conférence Annuelle Mondiale de la Santé Barclays (11-13 mars, Miami).
La direction participera à des discussions informelles et à des réunions individuelles avec les investisseurs lors de la plupart des événements, avec des présentations programmées le 12 février à 14h00 ET (Oppenheimer), le 3 mars à 9h50 ET (TD Cowen) et le 12 mars à 8h30 ET (Barclays). Les webcasts en direct et enregistrés des discussions informelles seront accessibles via le site Web des relations avec les investisseurs de TYRA.
Tyra Biosciences (NASDAQ: TYRA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Biologie des Fibroblast Growth Factor Receptors (FGFR) spezialisiert hat, hat seine Teilnahme an vier wichtigen Investorenkonferenzen Anfang 2025 angekündigt.
Das Unternehmen wird an der 35. Jahreskonferenz für Gesundheits- und Lebenswissenschaften von Oppenheimer (11.-12. Februar, virtuell), der 45. Jahreskonferenz für Gesundheit von TD Cowen (3.-5. März, Boston), dem Jefferies Biotech on the Beach Summit (11.-12. März, Miami) und der 27. Jahreskonferenz für globale Gesundheit von Barclays (11.-13. März, Miami) teilnehmen.
Das Management wird bei den meisten Veranstaltungen an informellen Gesprächen und Einzelgesprächen mit Investoren teilnehmen, mit Präsentationen, die für den 12. Februar um 14:00 Uhr ET (Oppenheimer), den 3. März um 9:50 Uhr ET (TD Cowen) und den 12. März um 8:30 Uhr ET (Barclays) angesetzt sind. Live- und aufgezeichnete Webcasts der informellen Gespräche sind über die Investor Relations-Website von TYRA zugänglich.
- None.
- None.
- Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025
- Format: Fireside chat and one-on-one investor meetings
- Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET
- Location: Virtual
- TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025
- Format: Fireside chat and one-on-one investor meetings
- Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET
- Location:
Boston
- Jefferies Biotech on the Beach Summit, March 11-12, 2025
- Format: One-on-one investor meetings
- Location:
Miami
- Barclays 27th Annual Global Healthcare Conference, March 11-13, 2025
- Format: Fireside chat and one-on-one investor meetings
- Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET
- Location:
Miami
A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302373952.html
SOURCE Tyra Biosciences
FAQ
What investor conferences will TYRA attend in February and March 2025?
When is TYRA's presentation at the Oppenheimer Healthcare Conference 2025?
How can investors access TYRA's conference presentations in 2025?
What is the format of TYRA's participation in the 2025 investor conferences?
Where will TYRA's March 2025 conference presentations take place?
